Leukemia, Lymphocytic, Acute, L1
Leukemia, Lymphocytic, Acute, L1
Explore linked clinical trials. Standard reference: MESH:M00238118 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Childhood Cancer Survivors' Affective Response to Exercise | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not stated | 2026-08-28 | NCT05763290 | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT05495035 | |
| Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Not applicable | 2026-07-08 | NCT06050850 | |
| Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute lymphoblastic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-06-29 | NCT03571321 | |
| CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-01-23 | NCT06326463 | |
| Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia | Chemically-Induced Disorders, Disease Attributes, Drug Toxicity, Drug-Related Side Effects and Adverse Reactions, Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, childhood malignant neoplasm, disease susceptibility, hematologic disorder, immune system disorder, immunoproliferative disorder, inherited disease susceptibility, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2026-01-15 | NCT05512169 | |
| PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-06-17 | NCT03817320 | |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2021-09-14 | NCT05043571 |